Quick Answer
NEKTAR THERAPEUTICS reported R&D Expense of $117.33 million for fiscal year 2025.
NEKTAR THERAPEUTICS R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $117.33M | -3.0% |
| 2024 | $120.91M | +5.9% |
| 2023 | $114.16M | -47.7% |
| 2022 | $218.32M | -45.5% |
| 2021 | $400.27M | -2.1% |
| 2020 | $408.68M | -6.0% |
| 2019 | $434.57M | +8.8% |
| 2018 | $399.54M | +48.8% |
| 2017 | $268.46M | +31.7% |
| 2016 | $203.80M | +11.5% |
| 2015 | $182.79M | +23.7% |
| 2014 | $147.73M | -22.2% |
| 2013 | $190.01M | +27.8% |
| 2012 | $148.68M | +17.3% |
| 2011 | $126.77M | +17.3% |
| 2010 | $108.06M | +13.6% |
| 2009 | $95.11M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.25M | -22.2% | -8.8% |
| June 30, 2025 | $29.89M | +0.5% | -1.9% |
| March 31, 2025 | $30.48M | +11.2% | -13.0% |
| September 30, 2024 | $35.03M | +45.5% | +17.9% |
| June 30, 2024 | $29.72M | +0.1% | +8.5% |
| March 31, 2024 | $27.41M | -10.0% | +13.9% |
| September 30, 2023 | $24.07M | -28.3% | -18.9% |
| June 30, 2023 | $29.68M | -30.6% | -2.6% |
- NEKTAR THERAPEUTICS showed a decrease of -3.0% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, NEKTAR THERAPEUTICS’s r&d expense has grown by 23.4% (from $95.11 million to $117.33 million).
- The most recent figure is from NEKTAR THERAPEUTICS’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: